DNA Chip Research Inc
TSE:2397
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
7.4B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
204.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
152.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
75.9T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.2B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
37B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
30.6B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.6B USD |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
DNA Chip Research Inc
Glance View
DNA Chip Research, Inc. engages in the business of contract analysis and Deoxyribonucleic Acid (DNA) chip technology development services. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 29 full-time employees. The company went IPO on 2004-03-18. The Contract Research segment is engaged in the microarray, next-generation sequencing experiment analysis to universities and research institutes, pharmaceutical and food companies. The Diagnostic segemnt utilizes genetic analysis technology to disseminate tests corresponding to social needs on personalized medicine and undiseased society. The main menu of the diagnostic business is EGFR-NGS Check. The Research and Development segment includes research on cancer diagnosis technology using next generation sequencer, as well as the development of RNA check.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for DNA Chip Research Inc is -5.3%, which is above its 3-year median of -50.4%.
Over the last 3 years, DNA Chip Research Inc’s Net Margin has increased from -31.3% to -5.3%. During this period, it reached a low of -110.6% on Mar 31, 2023 and a high of -3.6% on Dec 31, 2024.
